COVID-19 and immunosuppressive therapy in dermatology

被引：6

作者：

Schwartz, Robert A. ^{[1
]}

Pradhan, Swetalina ^{[2
]}

Murrell, Dedee F. ^{[3
]}

Jafferany, Mohammad ^{[4
]}

Olisova, Olga Y. ^{[5
]}

Lomonosov, Konstantin M. ^{[5
]}

Lotti, Torello ^{[5
,6
]}

Goldust, Mohamad ^{[7
,8
]}

机构：

[1] Rutgers New Jersey Med Sch, Dept Dermatol, Newark, NJ USA

[2] All India Inst Med Sci, Dept Dermatol & Venereol, Patna, Bihar, India

[3] Univ New South Wales, St George Hosp, Dept Dermatol, Fac Med, Sydney, NSW, Australia

[4] Cent Michigan Univ, Coll Med, Saginaw, MI USA

[5] IM Sechenov First Moscow State Med Univ, Dept Dermatol & Venereol, Moscow, Russia

[6] Univ Studies Guglielmo Marconi, Dept Dermatol, Rome, Italy

[7] Univ Studies Guglielmo Marconi, Rome, Italy

[8] Univ Hosp Basel, Dept Dermatol, Basel, Switzerland

来源：

DERMATOLOGIC THERAPY | 2020年 / 33卷 / 06期

关键词：

COVID; 19; dermatology; immunosuppressive therapy; ATOPIC-DERMATITIS; DIAGNOSIS;

D O I：

10.1111/dth.14140

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Coronavirus 2019 (COVID 19) was first detected in December 2019 in China. It has become a pandemic. With concern about therapies that may decrease immunity and enhance the severity of an individual's COVID-19 infection, leading to a possibly fatal outcome, use of immunosuppressants has become an important concern. This work focuses on management of various skin diseases individuals lacking immunity to COVID-19 but requiring a systemic immunosuppressant, keeping in view the challenge of the COVID 19 pandemic and that our knowledge of this virus and its effects on the immune system are incomplete including knowledge as to an individual's immunity after COVID-19 infection.

引用

页数：6

共 50 条

[21] COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy
Kolla, Epiphane
Weill, Alain
Zaidan, Mohamad
De Martin, Eleonora
De Verdiere, Sylvie Colin
Semenzato, Laura
Zureik, Mahmoud
Grimaldi, Lamiae
JAMA NETWORK OPEN, 2023, 6 (11)
[22] COVID-19 and Immunosuppressive Therapy in Ocular Inflammatory Disease, a Telemedicine Survey
Ebrahimiadib, Nazanin
Fadakar, Kaveh
Riazi-Esfahani, Hamid
Zarei, Mohammad
Maleki, Arash
Bojabadi, Leila
Ahmadi, Amin
Look-Why, Sydney
Foster, Charles Stephen
OCULAR IMMUNOLOGY AND INFLAMMATION, 2021, 29 (04) : 734 - 740
[23] Reflections of COVID-19 on Dermatology Practice
Richardson, Veronica L.
Garcia-Albea, Victoria R.
Bort, Nicole L.
Mayne, Susan L.
Nolen, Mary E.
Bobonich, Margaret A.
JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION, 2021, 13 (01) : 49 - 53
[24] Dermatology and COVID-19: The Hidden Pandemic
Recalcati, S.
Nazzaro, G.
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
[25] Dermatology Battles COVID-19 With Comfort
Parlette, Eric C.
CUTIS, 2020, 106 (06): : 313 - 314
[26] Challenges of COVID-19 pandemic for dermatology
Wollina, Uwe
DERMATOLOGIC THERAPY, 2020, 33 (05)
[27] Spanish Dermatology in the COVID-19 Era
Romani, J.
ACTAS DERMO-SIFILIOGRAFICAS, 2020, 111 (09): : 709 - 710
[28] Impact of COVID-19 on Dermatology Residency
Samimi, Sara
Choi, Juliana
Rosman, Ilana S.
Rosenbach, Misha
DERMATOLOGIC CLINICS, 2021, 39 (04) : 609 - 618
[29] Immunosuppressive Drugs and COVID-19: A Review
Schoot, Tessa S.
Kerckhoffs, Angele P. M.
Hilbrands, Luuk B.
van Marum, Rob J.
FRONTIERS IN PHARMACOLOGY, 2020, 11
[30] Impact of COVID-19 outbreak on dermatology services: Dermatology in isolation
Katerina, Damevska
Lence, Neloska
Viktor, Simeonovski
Andrej, Petrov
Irena, Dimitrovska
Natasa, Teovska-Mitrevska
Anita, Najdova
Nora, Pollozhani
DERMATOLOGIC THERAPY, 2020, 33 (04)

← 1 2 3 4 5 →